Sign in Create account

Anlon Healthcare Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AHCL BSE: 544497
₹34.58
▼ -1.81 (-4.97%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
76/100
Strong
Valuation
50/100
Fairly Valued
Momentum
78/100
Bullish

QVM read Quality in motion Quality Strong, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹1,838 Cr
PE (TTM)
6.2
Industry median 36.1 (152 companies)
Price to Book
7.2
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
2.89%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
19.9
Relative return vs Sector, qtr %
117.5
Free Cash Flow
₹-79 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-95.95%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
35.24%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-6.97%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.87
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.17
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
10.06
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
15.49%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
22.17%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
26.51%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
8.77%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
20.86%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
13.26%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 4 met
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.17)
  • No Return on equity is 15% or more (13.3%)
  • Yes Net cash flow for the latest year is positive

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-5.0%
Low 34.5800 · High 37.2400
1W return
16.5%
Low 27.7100 · High 37.2400
1M return
118.0%
Low 15.3200 · High 37.2400
52W return
-73.4%
Low 12.9100 · High 172.7500
Lifetime High ₹168.6100 (Nov. 28, 2025)
Lifetime Low ₹13.1100 (May 4, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish5
Bearish1
5D
33.2
10D
30.0
20D
25.6
50D
21.8
100D
31.8
200D
66.7

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
33.7%
Month avg. delivery
19.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

35.47
Pivot
First resistance36.35
Second resistance38.13
Third resistance39.01
First support33.69
Second support32.81
Third support31.03
Day RSI82.6
Day MFI88.6
Day MACD4.91
Day MACD signal3.50

Beta

1M1.81
3M0.08
1Y1.01
3Y1.10

Price change analysis

↑ 118.0%
Over 1 Month
LowHigh
15.3237.24
↑ 117.5%
Over 3 Months
LowHigh
13.8137.24
↓ -69.4%
Over 6 Months
LowHigh
12.91151.24
↓ -73.4%
Over 1 Year
LowHigh
12.91172.75
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 6.2 (own history: 2.9–14.4)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹31 Cr
Net profit (June 30, 2026)
₹5 Cr
Basic EPS (June 30, 2026)
₹0.0900

Ranks #81 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter52.68%
  • FII/FPI1.67%
  • Public44.43%

Largest holders

NameCategoryShares %Shares
PUNITKUMAR R RASADIAPromoter34.9800%185920000
MEET ATULKUMAR VACHHANIPromoter17.7000%94080000
SHREE DWARIKADHISH VENTURES LLPPublic7.5300%40000000
BAN LABS PRIVATE LIMITEDPublic5.2700%28000000
LUV NATWARLAL UKANIPublic1.1300%6000000

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 52.68% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.32% to 1.67% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 0 insider trades, 13 SAST, 0 pledge events →

All insider and SAST disclosures →

Deals (Bulk & Block)

All 196 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Buy 5,208,869 34.6600 NSE
30 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Sell 2,701,691 34.6200 NSE
30 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Sell 2,701,691 34.6200 NSE
30 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Buy 5,208,869 34.6600 NSE
29 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Sell 2,750,000 36.3900 NSE
29 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Buy 1,750,000 36.3900 NSE
29 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Sell 2,750,000 36.3900 NSE
29 Sep 2026 NEO APEX SHARE BROKING SERVICES LLP Bulk Buy 1,750,000 36.3900 NSE
25 Sep 2026 QE SECURITIES LLP Bulk Sell 2,825,885 29.8700 NSE
25 Sep 2026 QE SECURITIES LLP Bulk Buy 2,713,853 29.7200 NSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
13 Aug 2026 Other business matters —
11 Aug 2026 Other business matters —
30 Jul 2026 Financial Results/Other business matters Yes
29 May 2026 Financial Results Yes
6 Mar 2026 Bonus —

Corporate Announcements

All 7 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 Board Meeting Anlon Healthcare Ltd - 544497 - Board Meeting Intimation for Company''s Business Expansion Plans In India And/Or Overseas, And The Raising Of Funds/ Financing Thereof, In One Or More Tranches,
21 Sep 2026 Company Update Anlon Healthcare Ltd - 544497 - Announcement For Incorporation Of Foreign Subsidiary Of The Company
21 Sep 2026 Company Update Anlon Healthcare Ltd - 544497 - Announcement As Per Regulation 30 Of SEBI LODR.
16 Sep 2026 Company Update Anlon Healthcare Ltd - 544497 - Clarification sought from Anlon Healthcare Ltd
15 Sep 2026 Company Update Anlon Healthcare Ltd - 544497 - Announcement under Regulation 30 (LODR)-Credit Rating
5 Sep 2026 AGM/EGM Anlon Healthcare Ltd - 544497 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
5 Sep 2026 AGM/EGM Anlon Healthcare Ltd - 544497 - Shareholder Meeting / Postal Ballot-Outcome of AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.17)
  • Comfortable interest coverage (10.1x)
  • Healthy liquidity (Current Ratio 2.87)

Weaknesses

  • Declining revenue YoY (-7.0%)

Opportunities

  • PE below 15 (6.2) relative to a typical growth business

Threats

  • RSI in overbought territory (82.6)
  • Down 73.4% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Anlon Healthcare Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.